Yazar "Ozkilic, H." seçeneğine göre listele
Listeleniyor 1 - 12 / 12
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Alterations of gastric and esophageal functions in obese cases(Springer, 2009) Omur, O.; Erdogan, M.; Mutlukoca, N.; Saygili, F.; Ozkilic, H.; Yilmaz, C.Öğe Alterations of gastric and esophageal functions in obese cases(Springer, 2009) Omur, O.; Erdogan, M.; Mutlukoca, N.; Saygili, F.; Ozkilic, H.; Yilmaz, C.Öğe Assessment of Variables Associated with the Post-surgical Radioiodine Ablation of Thyroid Remnants(Springer, 2010) Akgun, A.; Omur, O.; Hatipoglu, F.; Uz, H.; Ozcan, Z.; Ozkilic, H.Öğe Clinical outcome and the value of diagnostic I-131 whole body scintigraphy and recombinant TSH in low-risk well differentiated thyroid cancer patients who have had I-131 radioablation and undetectable thyroglobulin levels(Springer, 2012) Argon, M.; Yararbas, U.; Kumanlioglu, K.; Ozkilic, H.Öğe Evaluation bone uptake of alendronate sodium via vaginal route by gamma scintigraphy, Vaginal uptake of alendronate sodium(Elsevier Science Bv, 2014) Ilem-Ozdemir, D.; Asikoglu, M.; Guneri, T.; Koseoglu, K.; Ozkilic, H.Alendronate sodium (ALD) is a second generation amino bisphosphonate that use for treatment of bone diseases. Since ALD is poorly absorbed from the gastrointestinal tract and its absorption is markedly reduced by food, the aim of this study is to evaluate the bone uptake of ALD through vaginal route. To evaluate the bone uptake of ALD by gamma scintigraphy. ALD was radiolabeled with Technetium-99m (Tc-99m). Vaginal suppositories and injectable solution of Tc-99m-ALD was prepared and gamma scintigraphy studies were performed with intravaginally and intravenously Tc-99m-ALD applied rabbits. The results were revealed that ALD was successfully labeled with Tc-99m. After intra vaginal and intravenous application, Tc-99m-ALD showed a high uptake in bone. Despite accumulation times and uptake ratios showed differences between administration routes, our preliminary observations suggest that the intravaginal route appears to be a viable alternative for ALD application and should be evaluated in future clinical studies.Öğe I-131 therapy in differentiated thyroid carcinoma patients with high thyroglobulin levels despite negative diagnostic I-131 scans(Springer, 2006) Akgun, A.; Yazici, B.; Erdim, O.; Ozcan, Z.; Ozkilic, H.Öğe Long-term evaluation of chromosomal breakages after radioisotope synovectomy for treatment of target joints in patients with haemophilia(Wiley-Blackwell, 2010) Kavakli, K.; Cogulu, O.; Aydogdu, S.; Ozkilic, H.; Durmaz, B.; Kirbiyik, O.; Özkınay, Ferda; Balkan, C.; Karapinar, D.; Ay, Y.Radioisotope synovectomy (RS) is defined as the intra-articular injection of radioisotopic agents with the aim of fibrosis on hypertrophic synovium in the target joint. The aim of this study was to investigate genotoxic effects on lymphocytes and malign transformation induced by Yttrium90 (Y90) and Rhenium186 (Re186) in children with haemophilia undergone RS. Forty haemophilia patients were enrolled. The mean age was 16.4 +/- 6.2 years (range: 8-40). Y90 was used for knees, Re186 was used for other joints. For safety, cytogenetic analysis was performed to determine potential chromosomal changes after RS procedure at three different time points as prior to procedure, 3rd day and 90th day. For the stimulation of chromosomal breakages, diepoxybutane was used (DEB test). Chromosomal breakages (CBs) were found in 23 patients (67.6%) prior to RS. We have found CBs additionally in nine of 11 patients who had no CBs prior to RS after 3 days of radioisotope exposure. At that time, the patients who had CBs were 29 (85.2%). At day 90, only 21 patients revealed (61.7%) CBs. The mean frequency of CBs slightly but not significantly increased in the 3rd day. However, there was a significant decreasing trend between 3rd and 90th days. Radioisotope synovectomy with Y90 and Re186 does not seem to induce the genotoxic effects significantly on peripheral blood lymphocytes. However, CBs even after one year in the re-evaluation of four patients, significant decrease in the number of CBs between the 3rd and 90th days and de novo CBs after exposure may be accepted as warning signals for young population. It should also be pointed out that families and patients be informed properly related with historical and potential dangers of radioisotopic agents.Öğe The management of well differentiated carcinoma of the ectopic thyroid tissue(Springer, 2007) Oral, A.; Mutlukoca, N.; Yararbas, U.; Ozcan, Z.; Ozkilic, H.Öğe Nitrate-enhanced Tc-99m MIBI gated SPECT for evaluating viable myocardium and left ventricular functions in patients with coronary artery disease(Springer, 2010) Omur, O.; Akgun, A.; Ozcan, Z.; Yanarates, A.; Calkavur, T.; Yavuzgil, O.; Ozkilic, H.Öğe Screening for metastasis in primary breast cancer patients having four or more axillary lymph node involvement: is it really necessary?(Imprimatur Publications, 2010) Uslu, R.; Kapkac, M.; Karaca, B.; Camyar, H.; Durusoy, R.; Ozdemir, N.; Aras, A. B.; Oktay, A.; Ozkilic, H.; Yilmaz, R.Purpose: To evaluate the necessity and direct cost effectiveness of screening and staging procedures in breast cancer patients having >= 4 positive axillary lymph nodes and to identity further possible biopathological risk factors associated with increased risk of metastasis. Methods: We reviewed the demographic and clinicopathological data from the medical records of 1897 newly diagnosed breast cancer patients. Patients having >= 4 positive axillary lymph nodes after primary surgery for breast cancer and who had staging examinations for metastasis were eligible. The impact of staging procedures (thoracoabdominal CT, bone scan etc.) for detecting metastasis, decision of adjuvant treatment and direct costs were analyzed in 329 patients with operable breast cancer Results: Thirty-five (10.6%) patients were found with metastasis at diagnosis. Seven (20.0%) among them had multiple metastases. Eighteen (51.4%) had lung, 17(48.6%) bone, and 7 (20.0%) liver metastasis. Twenty-one (60.0%) patients needed further radiological investigation for metastasis confirmation. Treatment decision was changed in 27 (77.1%) patients. No statistically significant risk factor was identified among the metastatic patients by means of conventional demographic and biopathological parameters. The cost of screening was lower when compared to the cost of treatment without any screening procedure. Conclusion: Since the conventional clinicopathological data seems not sufficient to define the risk of developing metastasis in breast cancer patients with >= 4 axillary lymph node involvement, all of them should undergo full staging examinations until new parameters based on genomic level are defined. Staging procedures need modification for high risk breast cancer patients.Öğe Serum thyroglobuline at the time of remnant ablation in predicting clinical outcome in patients with low risk differentiated thyroid carcinoma(Springer, 2006) Akgun, A.; Erdim, O.; Yazici, B.; Ozcan, Z.; Ozkilic, H.Öğe The use of TgAbs as a marker in differentiated thyroid cancer after ablation theraphy(Springer, 2006) Yazici, B.; Akgun, A.; Erdim, O.; Duygun, U.; Ozkilic, H.